| Model Number |
D132701 |
| Medical Device Problem Codes |
Insufficient Device Problem Information (3190); Patient Device Interaction Problem (4001)
|
| Health Effect - Clinical Codes |
Pericarditis (4448); Insufficient Information (4580)
|
| Date of Event |
01/10/2023
|
|
Type of Reportable Event
|
Serious Injury
|
|
Event or Problem Description
|
|
This complaint is from a literature source.The following literature cite has been reviewed: van der heijden caj, weberndörfer v, vroomen m, luermans jg, chaldoupi sm, bidar e, vernooy k, maessen jg, pison l, van kuijk smj, la meir m, crijns hjgm, maesen b.Hybrid ablation versus repeated catheter ablation in persistent atrial fibrillation: a randomized controlled trial.Jacc clin electrophysiol.2023 jan 10:s2405-500x(22)01143-4.Doi: 10.1016/j.Jacep.2022.12.011.Epub ahead of print.Pmid: 36752455.Objective/methods/study data:the purpose of this study was to compare the effectiveness and safety of ha with ca in a prospective, superiority, unblinded, randomized controlled trial.Lot, model and catalog number are not available, but the suspected biosense device possibly associated with reported adverse events: hybrid procedure (ha): 3.5-mm tip ablation catheter (thermocool smarttouch, biosense webster) other biosense webster devices that were also used in this study: catheter ablation (ca): an irrigated tip contact force mapping catheter (thermocool smarttouch, biosense webster), automated lesion tagging (visitag, biosense webster) non-biosense webster devices that were also used in this study: bipolar radiofrequency (rf)-clamp (synergy system, atricure), unidirectional bipolar rf pen (coolrail, atricure), epicardial clipping device (atriclip pro or atriclip pro 2, atricure) or an laa closure device (lariat, sentreheart), adverse event(s) and provided interventions: in the ha, 1 patient had a pericarditis requiring pericardiocentesis.In the ha group - 1 patient underwent a staged epi/endocardial procedure due to malfunction of the equipment for the endocardial ablation.
|
| |
|
Additional Manufacturer Narrative
|
|
This complaint is from a literature source.The following literature cite has been reviewed: van der heijden caj, weberndörfer v, vroomen m, luermans jg, chaldoupi sm, bidar e, vernooy k, maessen jg, pison l, van kuijk smj, la meir m, crijns hjgm, maesen b.Hybrid ablation versus repeated catheter ablation in persistent atrial fibrillation: a randomized controlled trial.Jacc clin electrophysiol.2023 jan 10:s2405-500x(22)01143-4.Doi: 10.1016/j.Jacep.2022.12.011.Epub ahead of print.Pmid: 36752455.No device was received for analysis at the time of submission of the initial 3500a.Since the product was not returned for analysis, no product failure analysis can be conducted, and no determination of possible contributing factors could be made.Device history record (dhr) review cannot be conducted because no lot number was provided by the customer.This report is being submitted pursuant to the provisions of 21 cfr, part 803.This report may be based on information which has not been investigated or verified prior to the required reporting date.This report does not reflect a conclusion by biosense webster, inc., or its employees that the report constitutes an admission that the product, biosense webster, inc., or its employees caused or contributed to the potential event described in this report.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.Manufacturer's ref #: (b)(4).
|
| |
|
Search Alerts/Recalls
|
|